MMP2 expression is a prognostic marker for primary melanoma patients

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

(2011) F. Su et al.   CANCER RESEARCH

Loss of phosphatase and tensin homolog enhances cell invasion and migration through aKT/Sp-1 transcription factor/matrix metalloproteinase 2 activation in hepatocellular carcinoma and has clinicopathologic significance

(2011) Karen Man-Fong Sze et al.   HEPATOLOGY

A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53

(2011) Anne Väisänen et al.   HUMAN PATHOLOGY

Prognostic Significance of Mitotic Rate in Localized Primary Cutaneous Melanoma: An Analysis of Patients in the Multi-Institutional American Joint Committee on Cancer Melanoma Staging Database

(2011) John F. Thompson et al.   JOURNAL OF CLINICAL ONCOLOGY

Optimizing the Frequency of Follow-Up Visits for Patients Treated for Localized Primary Cutaneous Melanoma

(2011) Robin M. Turner et al.   JOURNAL OF CLINICAL ONCOLOGY

Reducing mortality in individuals at high risk for advanced melanoma through education and screening

(2011) Alan C. Geller et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Loss of SNF5 Expression Correlates with Poor Patient Survival in Melanoma

(2009) H. Lin et al.   CLINICAL CANCER RESEARCH

National Assessment of Melanoma Care Using Formally Developed Quality Indicators

(2009) Karl Y. Bilimoria et al.   JOURNAL OF CLINICAL ONCOLOGY

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma

(2008) Anne H. Väisänen et al.   HUMAN PATHOLOGY

A Decade of Tissue Microarrays: Progress in the Discovery and Validation of Cancer Biomarkers

(2008) Robert L. Camp et al.   JOURNAL OF CLINICAL ONCOLOGY